Exosome Sciences
Company Snapshot
Company Overview
Exosome Sciences, a subsidiary of Aethlon Medical, is discovering and commercializing exosome-based biomarkers for diagnosing and monitoring Alzheimer’s disease, chronic traumatic encephalopathy (CTE) and other neurological disorders.
The company’s TauSome biomarker is being clinically studied by the Boston University CTE Center as part of the Detect Study.
In September 2019, Exome Sciences formed a partnership with Hoag Memorial Hospital. The partners agreed to launch a study to identify and characterize potential early disease markers for cancer diagnostics, cancer progression and treatment resistance.
In September 2019, Exosome’s parent, Aethlon Medical, received a $1.9 million award from the National Cancer Institute to develop Hemopurifier, a benchtop instrument that isolates exosomes from biofluids for applications in cancer research and clinical care.
Exosome Sciences In Reports
Exosome Sciences In News
Company's Business Segments
- Biomarkers : The company discover and develop exosome-based biomarkers for diagnosing and monitoring neurological disorders like Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).
Applications/End User Industries
- Hospitals and Clinical Testing Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
